-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

NK cells, An Attractive Allogeneic Cell Source for Treatment of Multiple Myeloma

Program: Scientific Workshops @ ASH
Session: CAR-T and Other Cellular Therapy for Mutiple Myeloma
Thursday, December 3, 2020, 9:12 AM-9:57 AM

Michael O'Dwyer, MD

School of Medicine, National University of Ireland Galway, Galway, Ireland

Disclosures: O'Dwyer: ONK Therapeutics: Consultancy, Current Employment, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties, Research Funding; AbbVie: Consultancy; Janssen: Consultancy, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Adaptive Biotechnologies: Consultancy, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Carrick Therapeutics: Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; BMS: Research Funding; Celgene: Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company).

See more of: CAR-T and Other Cellular Therapy for Mutiple Myeloma
See more of: Scientific Workshops @ ASH
Previous Presentation | Next Presentation >>